Retatrutide 20mg
$300.00
1 box (10 vials)
| Title | Range | Discount |
|---|---|---|
| Bulk/tiered discount | 15 - 25 | 5% $285.00 |
| Bulk/tiered discount | 26 - 50 | 10% $270.00 |
| Bulk/tiered discount | 51 - 100 | 15% $255.00 |
| Bulk/tiered discount | 101 + | 20% $240.00 |
Buy Retatrutide 20mg: Triple Agonist Peptide for Metabolic & Obesity Research
Retatrutide (20mg) is a next-generation triple hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. It is one of the most promising peptides in metabolic research for its powerful effects on weight loss, appetite suppression, energy expenditure, glucose control, and fat metabolism. Retatrutide is extensively studied for its superior potential in obesity and type 2 diabetes models compared to dual agonists.
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈ Molecular Weight: 4813.5 g/mol (approximate) Purity: ≥99% (lyophilized, research-grade)
Important Notice: This peptide is strictly intended for research and laboratory use only. Not for human consumption, diagnostic, therapeutic, or veterinary purposes. Please review and agree to our Terms and Conditions before ordering.
What is Retatrutide?
Retatrutide is a synthetic multi-agonist peptide engineered to target three key metabolic pathways at once:
- GLP-1 receptor — enhances insulin secretion and reduces appetite
- GIP receptor — improves insulin sensitivity and lipid metabolism
- Glucagon receptor — boosts energy expenditure and promotes lipolysis
This triple mechanism allows Retatrutide to deliver more comprehensive metabolic effects than single or dual agonists, making it a leading compound in current obesity and incretin research.
Mechanism of Action in Research
In experimental models, Retatrutide:
- Strongly suppresses appetite and food intake
- Increases energy expenditure via glucagon receptor activation
- Promotes significant reduction in body weight and visceral fat
- Improves glycemic control and insulin sensitivity
- Enhances lipid profiles and overall metabolic health
Research data suggest Retatrutide may achieve greater weight loss than currently available dual GLP-1/GIP agonists.
Key Research Areas
Retatrutide is primarily investigated for:
- Obesity and severe weight management models
- Type 2 diabetes and glycemic regulation
- Metabolic syndrome and lipid metabolism
- Energy balance and thermogenesis studies
- Comparative trials with tirzepatide and semaglutide
The 20mg vial size is ideal for dose-response studies, titration research, and medium-scale metabolic experiments.
Research Applications
The 20mg vial supports:
- Dose-escalation and chronic administration studies
- Obesity and metabolic disease animal models
- Body composition and fat mass analysis
- Comparative multi-agonist research
- Long-term metabolic and energy expenditure measurements
Why Choose 99% Pure Retatrutide 20mg?
Our Retatrutide 20mg offers ≥99% purity for reliable and reproducible results in receptor activation, appetite regulation, and metabolic endpoint studies. Third-party tested and lyophilized for optimal stability.
In summary, Retatrutide 20mg is a cutting-edge triple agonist peptide for advanced research into weight loss, obesity, glucose control, energy expenditure, and metabolic health. Advance your incretin and multi-receptor agonist studies with this high-potency research tool.
Latest Testing: Link to Report

Reviews
There are no reviews yet.